Close

Drug Research

RayBiotech screening assays used to identify chemoresistance pathway

RayBiotech-developed antibody-based biomarker screening assays have been used to identify a critical pathway involved in chemotherapeutic resistance acquired by melanoma cancer cells. RayBiotech president and chief operating officer Rani Huang said the findings of...

Elsevier integrates Reaxys with electronic laboratory notebook

PerkinElmer has integrated its electronic laboratory notebook (ELN) with Elsevier's Reaxys, a web-based workflow solution designed for chemistry researchers in drug discovery, chemicals and academic research. PerkinElmer Informatics general manager Michael Stapleton said as...

Alnylam and Ascletis collaborate to develop ALN-VSP for liver cancers in China

Alnylam Pharmaceuticals and Ascletis Pharmaceuticals have entered into a partnership to develop a systemically delivered RNAi therapeutic, ALN-VSP, for the treatment of liver cancers including hepatocellular carcinoma (HCC). Under the agreement, Ascletis gained an...

Takeda signs Omontys injection supply contract with Fresenius

Takeda Pharmaceuticals America (TPA) has signed a contract to supply Omontys injection to Fresenius Medical Care North America and certain of its affiliates. Omontys (peginesatide) injection is a synthetic, pegylated, peptide-based erythropoiesis-stimulating agent (ESA)...

Boehringer, Eli Lilly to launch diabetes drug in India

Boehringer Ingelheim India and Eli Lilly India is set to launch Linagliptin (brand name trajenta) 5mg film-coated tablets, for Type 2 diabetes in adults, in India. Linagliptin, which is approved in the US, the...

BioBlocks, Full Spectrum to develop new small molecule therapeutics

Full Spectrum Genetics and BioBlocks have signed an agreement to find new Small Molecule Therapeutics for protein-protein interactions. As part of the agreement, Full Spectrum Genetics protein analysis and engineering platform, MapEng, and BioBlocks'...

Mylan receives FDA approval for generic Lipitor ANDA

Mylan Laboratories, formerly Matrix Laboratories, has gained final FDA approval for its abbreviated new drug application (ANDA) of Atorvastatin Calcium Tablets of strengths 10mg, 20mg, 40mg and 80mg. The company begins immediate shipment of...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read